ADC Therapeutics SA (ADCT) Tops Q2 EPS by 14c
Tweet
Share
E-mail
Get Alerts ADCT Hot Sheet
Join SI Premium – FREE
ADC Therapeutics SA (NYSE: ADCT) reported Q2 EPS of ($0.25), $0.14 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $18.84 million versus the consensus estimate of $18.05 million.
For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evogene (EVGN) Tops Q2 EPS by 15c
- Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
- H.C. Wainwright Reiterates Buy Rating on Hive Digital Technologies (HIVE)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
